Bering Capital

Transforming Healthcare

Developing the early DNA of business through trust and culture

Navigating innovative business with early strategic insights

Reliable expertise in a volatile world

Creating a new world with fundamentally strong companies

Passionate about the future, visionary in how to build it

We believe in the primacy of great markets and great people all aligned with one mission

About Us

Seasoned partners in navigating varied stages of growth

People

We help build great companies with inspiration and support

Companies

Latest News

View All

08.02.2022

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

06.02.2022

Cellworks Singula Therapy Response Index (TRI) Predicts Clinical Outcomes For Esophageal Adenocarcinoma: MyCare-004

06.02.2022

Predictions of Overall Survival (OS) And Progression-Free Survival (PFS) For Specific Therapeutic Interventions In Newly Diagnosed Glioblastoma Multiforme (GBM) Using Cellworks Singula: myCare-024-04.

04.14.2022

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States